{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:43:16Z","timestamp":1792791796519,"version":"4.5.0"},"reference-count":32,"publisher":"Centers for Disease Control MMWR Office","issue":"46","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6846a5","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T11:00:33Z","timestamp":1574334033000},"page":"1069-1075","source":"Crossref","is-referenced-by-count":317,"title":["Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged \u226565 Years: Updated Recommendations of the Advisory Committee on Immunization Practices"],"prefix":"10.15585","volume":"68","author":[{"given":"Almea","family":"Matanock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gierke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Leidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pilishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R1","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R2","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"61","author":"CDC","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R3","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).","volume":"59","author":"CDC","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R4","first-page":"258","article-title":"Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children\u2014Advisory Committee on Immunization Practices (ACIP), 2010.","volume":"59","author":"CDC","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"64","author":"Kobayashi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R7","doi-asserted-by":"crossref","unstructured":"Pilishvili T, Almendares O, Nanduri S,  Evaluation of pneumococcal vaccines effectiveness against invasive pneumococcal disease (IPD) among U.S. Medicare beneficiaries \u226565 years old. Presented at the International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia; April 15\u201319, 2018.","DOI":"10.1093\/ofid\/ofy209.021"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R8","unstructured":"Pilishvili T, Almendares O, Xing W,  Effectiveness of pneumococcal vaccines against invasive pneumococcal disease (IPD) among adults >65 years old. Presented at the International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia; April 15\u201319, 2018."},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R9","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/cid\/ciy312","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design.","volume":"67","author":"McLaughlin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R10","doi-asserted-by":"publisher","first-page":"e019034","DOI":"10.1136\/bmjopen-2017-019034","article-title":"Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort.","volume":"8","author":"Prato","year":"2018","journal-title":"BMJ Open"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R11","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1016\/j.vaccine.2018.05.097","article-title":"A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.","volume":"37","author":"Gessner","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R12","unstructured":"Lessa FC, Spiller M. Effectiveness of PCV13 in adults hospitalized with pneumonia using Centers for Medicare & Medicaid data, 2014\u20132017. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; February 2019."},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R13","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.4161\/hv.27998","article-title":"Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.","volume":"10","author":"Juergens","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R14","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1080\/21645515.2015.1030550","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.","volume":"11","author":"Shiramoto","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4161\/hv.34420","article-title":"Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly.","volume":"11","author":"Durando","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R16","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1016\/j.vaccine.2016.10.052","article-title":"Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged \u226519 years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012\u2013December 31, 2015.","volume":"34","author":"Haber","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.vaccine.2017.12.061","article-title":"Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74\u202fyears of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R18","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.4161\/hv.28633","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged \u226550 years. An open-label trial.","volume":"10","author":"Shiramoto","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1128\/CVI.00711-14","article-title":"Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults \u226550 years of age in Mexico.","volume":"22","author":"Tinoco","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofy100","article-title":"Pneumococcal conjugate vaccine safety in elderly adults.","volume":"5","author":"Tseng","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R21","unstructured":"Food and Drug Administration. Highlights of prescribing information (package insert). Pneumovax 23 (pneumococcal vaccine polyvalent). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2017. https:\/\/www.fda.gov\/media\/80547\/download"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R22","unstructured":"Pilishvili T, Gierke R, Xing W,  Changes in invasive pneumococcal disease (IPD) among adults following 6 years of 13-valent pneumococcal conjugate vaccine use in the U.S. Presented at the International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia; April 15\u201319, 2018."},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R23","unstructured":"Matanock A. Considerations for PCV13 use among adults \u226565 years old and a summary of the evidence to recommendations framework. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; June 2019."},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz739","article-title":"Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions\u2014United States.","author":"Ahmed","year":"2019.","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R25","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1183\/09031936.00183614","article-title":"Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.","volume":"45","author":"Rodrigo","year":"2015","journal-title":"Eur Respir J"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R26","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.vaccine.2017.04.032","article-title":"Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: a systematic review of the literature.","volume":"35","author":"Tsaban","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R27","unstructured":"Lessa FC. Impact of introduction of infant vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) on pneumonia and invasive pneumococcal disease (IPD) in the United States, 2005\u20132014. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 2018."},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R28","unstructured":"Gierke R. Estimating impact of 13-valent pneumococcal conjugate vaccine on pneumococcal pneumonia among US adults. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 2018."},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R29","unstructured":"Swerdlow D. Incidence of community-acquired pneumonia in a US adult population. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 2018."},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R30","unstructured":"Leidner AJ. Overview of three economic analyses of pneumococcal vaccinations at age 65. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; February 2019."},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s11606-016-3651-0","article-title":"Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States.","volume":"31","author":"Stoecker","year":"2016","journal-title":"J Gen Intern Med"},{"key":"key-10.15585\/mmwr.mm6846a5-201911211059-R32","unstructured":"Food and Drug Administration. Highlights of prescribing information (package insert). Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2010. https:\/\/www.fda.gov\/media\/107657\/download"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T11:00:41Z","timestamp":1574334041000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/68\/wr\/mm6846a5.htm?s_cid=mm6846a5_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":32,"journal-issue":{"issue":"46","published-online":{"date-parts":[[2019,11,22]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6846a5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736951489.793573939","asserted-by":"object"}]},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,22]]},"published":{"date-parts":[[2019,11,22]]}}}